Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Income from Continuing Operations (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Income from Continuing Operations readings, the most recent being 58951000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 142.82% year-over-year to 58951000.0, compared with a TTM value of 22356000.0 through Dec 2025, up 193.62%, and an annual FY2025 reading of 22388000.0, up 193.82% over the prior year.
  • Income from Continuing Operations hit 58951000.0 in Q4 2025 for Apellis Pharmaceuticals, down from 215717000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 283396000.0 in Q4 2021, with the low at 219191000.0 in Q2 2021.
  • Median Income from Continuing Operations over the past 5 years was 87700500.0 (2022), compared with a mean of 68301900.0.
  • The largest YoY upside for Income from Continuing Operations was 475.52% in 2025 against a maximum downside of 142.82% in 2025.
  • Year by year, Income from Continuing Operations stood at 283396000.0 in 2021, then plummeted by 129.35% to 83176000.0 in 2022, then soared by 51.8% to 40090000.0 in 2023, then surged by 443.38% to 137662000.0 in 2024, then plummeted by 142.82% to 58951000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 58951000.0, 215717000.0, and 42185000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.